Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Phase 3

Active, not recruiting

Conditions: Ganglioneuroblastoma
Neuroblastoma

Interventions: Procedure: Autologous Hematopoietic Stem Cell Transplantation
Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration and Biopsy
Drug: Carboplatin
Drug: Busulfan
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Cyclophosphamide
Drug: Dexrazoxane Hydrochloride
Biological: Dinutuximab
Drug: Doxorubicin Hydrochloride
Procedure: Echocardiography
Drug: Etoposide Phosphate
Radiation: External Beam Radiation Therapy
Radiation: Iobenguane I-123
Drug: Isotretinoin
Radiation: Iobenguane I-131
Procedure: Multigated Acquisition Scan
Drug: Lorlatinib
Drug: Melphalan Hydrochloride
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Biological: Sargramostim
Procedure: Therapeutic Conventional Surgery
Drug: Thiotepa
Drug: Topotecan Hydrochloride
Drug: Vincristine Sulfate

First Posted Date: 2017-04-25

Last Posted Date: 2024-12-04

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 724

Registration Number: NCT03126916

Locations: 🇺🇸
Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
🇺🇸
Henry Ford Health Saint John Hospital, Detroit, Michigan, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 158 locations

Auto Stem Cell Transplant for Lymphoma Patients

Phase 2

Recruiting

Conditions: Hodgkin Lymphoma
Non-Hodgkin Lymphoma

Interventions: Procedure: Peripheral blood stem cell transplantation
Drug: Etoposide
Biological: G-CSF
Drug: BCNU
Drug: AraC
Drug: Cyclophosphamide
Drug: Melphalan
Radiation: Total Body Irradiation

First Posted Date: 2017-04-24

Last Posted Date: 2024-11-04

Lead Sponsor: Masonic Cancer Center, University of Minnesota

Target Recruit Count: 150

Registration Number: NCT03125642

Locations: 🇺🇸
Masonic Cancer Center, University of Minnesota, Minneapolis, Minnesota, United States

Study of Adoptive Cellular Therapy Using Autologous T Cells Transduced With Lentivirus to Express a CD33 Specific Chimeric Antigen Receptor in Patients With Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Hematopoietic/Lymphoid Cancer
Acute Myeloid Leukemia

Interventions: Procedure: Leukapheresis
Drug: Fludarabine
Drug: Cyclophosphamide
Biological: CD33-CAR-T Cell Infusion

First Posted Date: 2017-04-24

Last Posted Date: 2019-11-04

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 11

Registration Number: NCT03126864

Locations: 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Efficacy and Safety of Neoadjuvant DC-T in Breast Cancer Patients

Phase 4

Conditions: Breast Cancer

Interventions: Drug: Pegylated liposomal doxorubicin
Drug: Cyclophosphamide
Drug: Epirubicin
Drug: Docetaxel

First Posted Date: 2017-04-21

Last Posted Date: 2019-04-10

Lead Sponsor: Zhejiang University

Target Recruit Count: 384

Registration Number: NCT03123770

Locations: 🇨🇳
Cancer institute, Hangzhou, Zhejiang, China

Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease

Phase 2

Recruiting

Conditions: Sickle Cell Disease

Interventions: Drug: ATG
Drug: fludarabine
Drug: cyclophosphamide
Radiation: Total body irradiation
Procedure: Stem cell infusion
Drug: Sirolimus
Drug: mycophenolate mofetil

First Posted Date: 2017-04-19

Last Posted Date: 2024-11-12

Lead Sponsor: University of Illinois at Chicago

Target Recruit Count: 50

Registration Number: NCT03121001

Locations: 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

Phase 2

Active, not recruiting

Conditions: Acute Lymphoblastic Leukemia
Acute Lymphoblastic Lymphoma

First Posted Date: 2017-04-18

Last Posted Date: 2024-11-26

Lead Sponsor: St. Jude Children's Research Hospital

Target Recruit Count: 790

Registration Number: NCT03117751

Locations: 🇺🇸
Children's Hospital of Michigan, Detroit, Michigan, United States
🇺🇸
St. Jude Affiliate Clinic - Novant Health Hemby Children's Hospital, Charlotte, North Carolina, United States
🇦🇺
The Royal Children's Hospital Melbourne, Parkville, Victoria, Australia

and more 5 locations

Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis

Phase 1

Active, not recruiting

Conditions: Secondary Myelofibrosis

Interventions: Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
Drug: Cyclophosphamide
Drug: Fludarabine
Biological: Glycosylated Recombinant Human G-CSF AVI-014
Other: Laboratory Biomarker Analysis
Drug: Melphalan
Drug: Mycophenolate Mofetil
Drug: Tacrolimus
Radiation: Total-Body Irradiation

First Posted Date: 2017-04-18

Last Posted Date: 2024-10-30

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 22

Registration Number: NCT03118492

Locations: 🇺🇸
City of Hope Medical Center, Duarte, California, United States

Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma

Phase 2

Active, not recruiting

Conditions: Ann Arbor Stage III Noncutaneous Anaplastic Large Cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Angioimmunoblastic T-Cell Lymphoma
Ann Arbor Stage II Noncutaneous Anaplastic Large Cell Lymphoma
Ann Arbor Stage IV Noncutaneous Anaplastic Large Cell Lymphoma
Hepatosplenic T-Cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Adult T-Cell Leukemia/Lymphoma
Anaplastic Large Cell Lymphoma, ALK-Negative
Anaplastic Large Cell Lymphoma, ALK-Positive

Interventions: Drug: Brentuximab Vedotin
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Doxorubicin Hydrochloride
Drug: Etoposide
Drug: Etoposide Phosphate
Other: Laboratory Biomarker Analysis
Drug: Prednisone

First Posted Date: 2017-04-13

Last Posted Date: 2024-02-20

Lead Sponsor: City of Hope Medical Center

Target Recruit Count: 48

Registration Number: NCT03113500

Locations: 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States

and more 2 locations

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

Phase 1

Conditions: Hematopoietic/Lymphoid Cancer
Refractory Chronic Lymphocytic Leukemia
B-cell Adult Acute Lymphoblastic Leukemia
Adult Acute Lymphoblastic Leukemia in Remission
B-cell Chronic Lymphocytic Leukemia

Interventions: Biological: anti-CD19 CAR-T
Drug: Fludarabine
Drug: Cyclophosphamide

First Posted Date: 2017-04-12

Last Posted Date: 2019-11-27

Lead Sponsor: First Affiliated Hospital of Wenzhou Medical University

Target Recruit Count: 20

Registration Number: NCT03110640

Locations: 🇨🇳
The First Affilicated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China

NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922)

Phase 1

Active, not recruiting

Conditions: Neuroblastoma

Interventions: Drug: Lorlatinib
Drug: Cyclophosphamide
Drug: Topotecan
Drug: Filgrastim/pegfilgrastim

First Posted Date: 2017-04-11

Last Posted Date: 2024-02-09

Lead Sponsor: New Approaches to Neuroblastoma Therapy Consortium

Target Recruit Count: 65

Registration Number: NCT03107988

Locations: 🇬🇧
Royal Marsden Hospital, Sutton, Surrey, United Kingdom
🇺🇸
Cook Children's Healthcare System, Fort Worth, Texas, United States
🇺🇸
Children's Healthcare of Atlanta, Atlanta, Georgia, United States

and more 10 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy